HomeCompareIFUS vs PFE

IFUS vs PFE: Dividend Comparison 2026

IFUS yields 8492.57% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IFUS wins by $11041986035131172.00M in total portfolio value
10 years
IFUS
IFUS
● Live price
8492.57%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11041986035131172.00M
Annual income
$10,792,008,505,664,056,000,000.00
Full IFUS calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — IFUS vs PFE

📍 IFUS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIFUSPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IFUS + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IFUS pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IFUS
Annual income on $10K today (after 15% tax)
$721,868.37/yr
After 10yr DRIP, annual income (after tax)
$9,173,207,229,814,447,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, IFUS beats the other by $9,173,207,229,814,447,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IFUS + PFE for your $10,000?

IFUS: 50%PFE: 50%
100% PFE50/50100% IFUS
Portfolio after 10yr
$5520993017565586.00M
Annual income
$5,396,004,252,832,028,000,000.00/yr
Blended yield
97.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

IFUS
No analyst data
Altman Z
7.4
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IFUS buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIFUSPFE
Forward yield8492.57%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$11041986035131172.00M$49.6K
Annual income after 10y$10,792,008,505,664,056,000,000.00$26,258.71
Total dividends collected$11025302406276466.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IFUS vs PFE ($10,000, DRIP)

YearIFUS PortfolioIFUS Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$859,957$849,256.90$9,153$693.39+$850.8KIFUS
2$69,174,764$68,254,610.41$8,593$849.25+$69.17MIFUS
3$5,205,220,238$5,131,203,240.18$8,336$1,066.78+$5205.21MIFUS
4$366,419,711,261$360,850,125,605.98$8,437$1,384.80+$366419.70MIFUS
5$24,132,183,173,475$23,740,114,082,425.72$9,013$1,875.40+$24132183.16MIFUS
6$1,487,045,477,053,427$1,461,224,041,057,809.20$10,306$2,680.72+$1487045477.04MIFUS
7$85,742,407,458,414,640$84,151,268,797,967,470.00$12,820$4,101.38+$85742407458.40MIFUS
8$4,626,441,795,368,287,000$4,534,697,419,387,782,700.00$17,673$6,826.70+$4626441795368.27MIFUS
9$233,623,859,315,062,280,000$228,673,566,594,018,200,000.00$27,543$12,591.86+$233623859315062.25MIFUS
10$11,041,986,035,131,173,000,000$10,792,008,505,664,056,000,000.00$49,560$26,258.71+$11041986035131172.00MIFUS

IFUS vs PFE: Complete Analysis 2026

IFUSStock

Impact Fusion International, Inc. engages in the business of marketing products in the health and wellness sector. The company focuses on the invention, development, and marketing of its proprietary products worldwide for the health of humans and animals. The company's products include Nutri-Mastic that supports digestive function, the immune system, vital organ health, healthy blood cells, and cardiac muscle and heart function; Intact Nutrition herbal health support products; Intact Endurance, which offers nutrients to increase body's optimal energy levels; Pet Intact nutritional supplements; and Equine Intact products. It also sells herbal health support beverages under the Mastic Blast Beverage brand; and alternative proprietary formulation for beef and dairy cattle under the Supreme Gold Plus brand. The company was formerly known as Red Reef Laboratories International, Inc. and changed its name to Impact Fusion International Inc. in April 2009. Impact Fusion International, Inc. was founded in 2002 and is based in Margate, Florida.

Full IFUS Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this IFUS vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IFUS vs SCHDIFUS vs JEPIIFUS vs OIFUS vs KOIFUS vs MAINIFUS vs JNJIFUS vs MRKIFUS vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.